Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme

Study Overview
=================
Brief Summary
-----------------
The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.

Official Title
-----------------
Biomaterial Collection for Neurodegenerative Disease Research (ND Collection)

Conditions
-----------------
Parkinson Disease

Intervention / Treatment
-----------------
* Other: Observational study with sample and data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism) Subjects of all genders with a full capacity of consent Subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement Subjects of at least 18 years of age at the time of inclusion Exclusion Criteria: Refusal to sign the informed consent Limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion Active cancer Pregnant women Underage subjects of less than 18 years of age Refusal to comply with mandatory sample collection For invasive procedures, i.e., lumbar puncture and skin biopsy: relevant blood clotting impairment, e.g., anamnestic evidence of frequent or prolonged bleedings.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PD patients<br>Subjects with neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism) | Other: Observational study with sample and data collection<br>* Observational study with sample and data collection<br>|
| Healthy controls<br>Gender- and age-matched healthy controls | Other: Observational study with sample and data collection<br>* Observational study with sample and data collection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1. Establish an open collection of a large set of diverse longitudinal bio-samples and data for research in 800 PD patients and 800 controls | 1.1. Samples will be aliquoted and stored according to the highest standards at the IBBL for future research. | through study completion, an average of 8 years | 
| 2. Stratification of parkinsonism into subtypes and definition of individual progression trajectories of PD. | 2.1. Identify PD patients' subgroups with a similar pattern of disease progression. datasets. | through study completion, an average of 8 years | 
| Determine Parkinson's disease biomarker signatures | 3.1. Identify new and early diagnostic biomarkers | through study completion, an average of 8 years | 
| Develop a mechanistic understanding of the disease | 4.1. Understand the mechanisms of PD pathogenesis. | through study completion, an average of 8 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inform future studies testing new therapies for Parkinson's disease | 1.1. Enable future studies, such as clinical trials, by sharing the findings of mechanisms of PD pathogenesis and identifying new therapeutic targets. | through study completion, an average of 8 years | 
| Harmonization of data with international Parkinson's disease cohort studies | 2.1. Data collected in this study will be harmonized with the international PD research community through an open-source digital platform. | through study completion, an average of 8 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson's disease, longitudinal cohort, stratification, risk factors